News
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...
The move makes Moderna’s vaccine, called Spikevax, the first COVID shot for kids in the U.S. to be fully approved, rather ...
The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...
1d
Barchart on MSNWhat to Expect From Moderna's Next Quarterly Earnings ReportModerna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in ...
The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...
The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...
The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, ...
The Food and Drug Administration (FDA) granted full approval on Thursday to Moderna’s COVID-19 vaccine for children, making it the first COVID shot for kids aged 6 months to 11 years old that is ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
StockStory.org on MSN1d
Why Moderna (MRNA) Stock Is Falling TodayWhat Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results